AlenCiken

NMRC received guidance from the FDA

NASDAQ:IMRN   Immuron Limited
NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC

-Two human phase II clinical trials to be conducted in 2021

-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis

-The second trial will focus on ETEC infections

https://finance.yahoo.com/news/us-dod-na...